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ABSTRACT
With the advancement of high-throughput biotechnologies, we increasingly accumulate biomedical data about diseases,
especially cancer. There is a need for computational models and methods to sift through, integrate, and extract new knowledge
from the diverse available data to improve the mechanistic understanding of diseases and patient care. To uncover molecular
mechanisms and drug indications for specific cancer types, we develop an integrative framework able to harness a wide range
of diverse molecular and pan-cancer data. We show that our approach outperforms competing methods and can identify
new associations. Furthermore, through the joint integration of data sources, our framework can also uncover links between
cancer types and molecular entities for which no prior knowledge is available. Our new framework is flexible and can be easily
reformulated to study any biomedical problems.
Introduction
Over 18 million new cases of cancer and 9 million deaths were recorded worldwide in 20181. This makes cancer one of the
leading causes of death. Cancer is a multi-faceted, complex disease arising from an accumulation of somatic mutations within
the genome of normal cells that eventually leads to loss of normal cellular functioning and appearance of tumours that can
spread across the body. Technological advances have enabled measurements from patient’s tumour biopsies, including gene
expression levels, DNA methylations, and somatic mutations. The research into cancer causes and treatments has greatly
benefited from this wealth of patient data2, 3.
Cancer projects, including The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC),
have made publicly available wide-ranging, multi-modal, multi-omics cancer data, such as patient whole slide images, genome
alterations, transcriptome, and epigenome4, 5. Free access to these large-scale, diverse databases has dramatically facilitated
studies of the biological mechanisms of specific cancer types4, 6, 7. The available data have also enabled pan-cancer analyses
that study cancer in general to identify common mechanisms and differences across cancer types7, 8. Recently, the Pan-Cancer
Analysis of Whole Genome (PCAWG) project7 has informed that our knowledge about cancer is far from complete, as 5% of
their cohort was without any known cancer driver mutations. Importantly, these large databases have paved the way for the field
of Precision Medicine, whose aim is to improve medical care for patients by tailoring treatment to their individual molecular
profiles9. This is especially relevant to a heterogeneous disease, such as cancer, which manifests uniquely in every patient.
Complex diseases, such as cancer, can be caused by combinations of genetic, molecular, environmental, and lifestyle factors.
Such diseases cannot be fully captured by any single type of biological data. As such, collective mining of different data has
been gaining momentum as a means to extract integrated system knowledge that goes beyond what any single data source can
offer10. This principle applied to the study of cancer has enabled the discovery of cancer-related genes, or group of genes11–13
and the identification of cancer sub-types significantly correlated with patient prognoses12, 14.
Biological data often have a small number of samples relative to the number of available features. For instance, a typical
dataset in TCGA contains a few hundred patients that are each characterised by tens of thousands of features (e.g., expression
levels of around 20,000 genes). However, biological features are often redundant due to underlying molecular interactions
among biological entities15. This has been a motivation for the use of dimensionality reduction and embedding algorithms that
are pervasive in bioinformatics16. Additionally, due to the low sample to features ratio, dimensionality reduction techniques are
often necessary as data pre-processing for machine learning models16.
Non-negative matrix factorisation (NMF) approaches are unsupervised algorithms that have extensively been used both as
a means to integrate heterogeneous data and to reduce data dimensionality. They encompass all methods that decompose a
matrix, representing relational links between two sets of entities, into the product of low-dimensional, latent, positive matrices,
or factors, whose sizes control the degree of dimensionality reduction17. Importantly, they can be used to derive an embedding
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in an unspecified latent space for each entity. Matrix factorization approaches have had numerous applications, including
collaborative filtering18 and biological data integration for cancer analysis12, 14. Reconstructing a matrix based on a factorisation
has often been used to make predictions and infer new knowledge12. However, unsupervised approaches often underperform
supervised machine learning methods in classification tasks. Hence, NMF approaches have been combined with downstream
machine learning classifiers19.
We propose a pan-cancer framework to uncover cancer type specific molecular mechanisms and identify drugs that could
be re-purposed (see Figure 1). Our framework relies on the simultaneous integration and dimensionality reduction of various
data using a joint non-negative matrix factorisation model. Our framework includes more data than the previous studies,
integrating patient-specific diagnosis, gene expression, and single nucleotide variants as well as generic network data on human:
protein–protein interactions, protein complex associations, biological pathways, drug–target interactions, and drug chemical
similarities. To integrates the wealth of data in one framework, we rely on three types of matrix factorisations: non-negative
matrix factorisation (NMF), non-negative matrix tri-factorisation (NMTF), and symmetric non-negative matrix tri-factorisation
(SNMTF). The details for each can be found in Methods. Data integration is achieved by jointly optimising for multiple
factorisation objectives with shared factors (see Methods). We obtain a context-aware embedding of each entity (cancer type,
patient, gene, complex, pathway, and drug) that takes into account all the input data. Using boosted decision trees, we predict
biologically relevant associations between cancer types and genes, drugs, pathways, and complexes based on the context-rich
embeddings of our entities. One key insight is that the integration step, by construction, embeds the entities into three latent
spaces that contain: 1) patients and cancer types, 2) genes, complexes, and pathways, and 3) drugs. This means that the
classifiers trained to predict associations for one entity can naturally be transferred to predict associations of another entity in
the same latent space. In this respect, our approach is similar to zero-shot learning20, which aims to accurately classify at test
time samples that belong to classes unseen at training time. In our case, we aim to predict the association of cancer types to
unseen entities at training time.
Results
Our framework for context-aware embeddings
The core of the framework is gene information (see Figure 1.a.). We integrate three types of data about genes. We obtain RNA
sequencing (RNA-seq) data and single nucleotide variants (SNV) data for 7,998 patients from ICGC (see Methods for details)
across 21 cancers. Henceforth, we refer to each cancer by its abbreviation given in Table 3. We obtain data on gene interactions
including protein-protein interaction (PPI) network from Biogrid, protein complexes (PC) from Reactome and Corum, and
biological pathways (BP) from Reactome (see Methods for details). These data capture physical and functional relationships
between genes and are used to anchor our framework within the context of molecular interactions. The last type of gene data
corresponds to drug–target interactions from DrugBank (see Methods for details), connecting drugs to proteins that they target.
We further add drug chemical similarity information to push similar drugs closer in the latent space. We also add patient
diagnosis information through which we embed cancer types and patients in a joint latent space to both push patients closer if
they have the same cancer and push molecularly similar cancer types closer. This could help tailor treatments to patients by
placing them within a cancer “space” since cancer is a heterogeneous disease and a given cancer type might manifest differently
in different people. This may aid characterising cancer of each patient as accurately as possible to personalise treatment options.
Because of the heterogeneity of our input data, our integration framework is based on joint optimisation of different variants
of non-negative matrix factorisation: classical Non-negative Matrix Factorisation (NMF), Non-negative Matrix Tri-Factorisation
(NMTF), and Symmetric Non-negative Matrix Tri-Factorization (SNMTF). Each variant, described in Methods, is best fitted
for the decomposition of a different type of relational data. In particular, we use SNMTF to factorise the PPI network and the
drug similarities matrix, NMTF to factorise patient molecular data and drug–target data, and NMF for the remaining data. Each
edge in Figure 1.a corresponds to a sub-objective of our embedding framework, i.e. a specific NMF decomposition. Each
group of entities is associated in the joint decomposition to a factor that is shared across all sub-objectives involving that group
of entities. For instance, the patient factor is shared by all sub-objectives that involves patient-specific data (diagnoses, gene
expressions, and somatic mutations). An entity’s embedding is obtained from the factor of the associated group of entities.
Through our integrative framework, we derive embeddings for all entities (cancer types, patients, genes, pathways,
complexes, and drugs) that best fit the full context of the framework, i.e. the input relational data. Each entity’s embedding, in
one of the three latent spaces learnt by our framework, encapsulates the information from the input data that is relevant to that
entity; thus we say that this representation is context-aware. Our framework has three hyperparameters, denoted by k1, k2 and
k3, which correspond to the dimensions of the latent spaces. To find suitable values for these hyperparameters, we perform
a grid search with k1 ∈ {2,5,10,15,21}, k2 ∈ {70,80,90,100,110}, and k3 ∈ {40,50,60,70,80}. As the selection criterion,
we measure if each patient tends to be embedded in the latent space closer to their diagnosis than to other cancer types. We
quantify this with the macro-F1 score of the classifier that associates to each patient the closest cancer type in the latent space
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Figure 1. a. Input to our matrix factorization embedding model: relational data between entities. Each edge corresponds to a
type of link and to a sub-objective of our joint factorisation model (see Methods Data Processing Table 4 for notation). The
squares group entities that are embedded in the same joint latent space. b. Illustration of the NMTF factorisation sub-objectives
corresponding to the edges in the grey box in panel a. Each group of entities is associated in the decomposition to a factor that
is shared across all sub-objectives involving that group of entities. Through the joint decomposition of all relational data, we
derive embeddings for each entity in three latent spaces with dimensions k1, k2, and k3. c. We predict associations relevant to
cancer types with boosted decision tree classifiers taking as input, for instance, the concatenation of the embeddings of a cancer
type and of a gene.
in terms of cosine distance. We found that the following hyperparameters values maximize this metric: k1 = 21, k2 = 70, and
k3 = 40. Supplementary Figure 1 shows the sensitivity of different metrics to the choice of the hyperparameters, which we
discuss in the rest of the article.
Patient and cancer embeddings are medically relevant
To evaluate the biomedical relevance of our joint patient and cancer embeddings, we observe that the macro-F1 score is close to
0.8 for our optimal set of hyperparameters (see Figure 2.a.) indicating that the majority of patients are embedded closer to their
diagnoses than to other cancer types. In addition, we evaluate if patients group in the latent space with respect to either cancer
type, or a sampled tissue. To this end, we use hierarchical clustering with cosine distance to group patients in k groups (where k
is either the number of cancers, or the number of tissues) and compute the Adjusted Rand Index (ARI) to measure the link
between the clustering and the ground truth labelling (either cancer types, or sampled tissues; see Figure 2.b.). We observe
that patients do not cluster well with respect to sampled tissues, having ARI below 0.2. However, we observe ARI 0.7 with
respect to cancer type, indicating that our clusterings resemble diagnostic labelling with some discrepancies. These results
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Figure 2. a. Macro-F1 score quantifying the relation between a patient and its cancer type (green) and adjusted random index
(ARI) measuring the link between patient clustering for each model and cancer type labelling (orange) and tissue sampled
labelling (blue). b. t-SNE plot representing the embedding of patients and cancer types in the latent space. The larger circled
markers correspond to the embeddings of cancer types, and the smaller ones represent the embeddings of patients. Colours and
shapes indicate cancer types (see Methods Table 3 for abbreviations meanings). c. Percentages of gene clusters enriched in
GO-BP, GO-CC, GO-MF, and driver annotations. d. Average cosine distance between genes and associated pathways and
complexes (intra-pathway and intra-complex) and non-associated pathways and complexes (exo-pathway and exo-complex).
are expected, as the inclusion of patient diagnosis data in the framework implies a constraint that aims to embed each patient
close to their diagnosis and subsequently, to other patients having the same disease. Note however, that some patients do not fit
well with the rest of their cohorts. This is an important observation, as it suggests that those patients might need different care
options from the majority of their cohort and further motivates personalising treatments to individual patients.
As an illustration, we visualise our latent space embeddings using T-distributed Stochastic Neighbor Embedding (t-SNE).
t-SNE is a machine learning algorithm for nonlinear dimensionality reduction, well-suited for visualisation in a two-dimensional
space of high-dimensional data21. We observe as expected that patients tend to cluster according to cancer type, with the
cancer type itself being also embedded nearby (see Figure 2.c.). Additionally, we observe that some cancers are grouped in a
meaningful way. For instance, both brain cancers, GBM and LGG, form one group. The cluster in the centre contains mostly
squamous cell carcinomas, HNSC, CESC, and LUSC. Both cancers that affect kidneys, KIRP and KIRC, are also grouped.
And READ, COAD, and STAD - which are cancers affecting rectum, colon, and stomach, respectively - form another cluster.
We also observe that some patients having a certain type of cancer do not group with the majority of the cohort.
We further investigate if our framework learns a meaningful latent space that translates into actionable representations for
new unseen patients. We perform a 10-fold cross-validation in which 90% of patients of each cancer type are used to derive
the embeddings of all entities in the framework. We then project the remaining 10% of patients in the derived cancer/patient
latent space (see Supplementary Methods). First, we test if these patients are placed close in space to their diagnosis (quantified
as above, see Supplementary Table 1). This gives a macro-F1 score of 0.77±0.03, which is close to the score obtained with
all patients included in the framework (∼ 0.8). This shows that new patients are placed in the latent space according to their
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diagnoses with accuracy similar to that for patients included in the framework. We also test if the unseen patients tend to be
embedded closer to patients having the same diagnoses. For this, we use a k-nearest neighbours classifier with k = 10 (see
Supplementary Methods) and measure its macro-F1 score (see Supplementary Table 1). We observe a score of 0.88±0.02,
which shows that the large majority of new patients are embedded in the latent space closer to patients diagnosed with the same
type of cancer. Both results show that our latent space is robust in the sense that we can derive an embedding for new patients
that is consistent with that of known patients and cancer types. We also observe that the k-nearest neighbour algorithm gives a
more robust diagnosis classifier than finding the closest cancer in the latent space. This means that the local neighbourhood of a
patient in the latent space is a better diagnosis indicator than a global predictor derived from cancer types’ embedding. This
suggests the presence of patient subgroups within a cancer type that display substantially different molecular behaviour.
Overall, our analysis shows that the patients/cancers latent space is consistent with known biology. Furthermore, our
framework has the advantage of relaxing the hard clustering derived from patients diagnoses through patient’s molecular
similarity, highlighting that a patient’s molecular profile can be more similar to the profiles of patients with different cancers
than to the profiles of patients with the same diagnosis. This observation motivates further the need for pan-cancer perspectives
in precision medicine.
Our gene latent space is biologically relevant
To evaluate the biological relevance of our genes embeddings, we cluster them in k2 group and measure the enrichments of the
clusters in terms of Gene Ontology (GO) annotations and in terms of cancer driver genes (see Methods for details). We consider
all three subtypes of GO annotations: Biological Processes (GO-BP), Cellular Component (GO-CC), and Molecular Function
(GO-MF) separately. The significance of the enrichments is computed with a hypergeometric test with Benjamini-Hochberg
correction for multiple hypothesis testing and a significance threshold of 0.05. We observe that, regardless of the GO subtype,
above 80% of clusters are significantly enriched in at least one annotation (see Figure 2.c.). These results show that genes
with similar function are embedded closer in the latent space and thus that our genes’ embeddings capture known biology.
Interestingly, we also observe that around 10% of the clusters are enriched in cancer driver genes, indicating that cancer drivers
are embedded closely, i.e. clustered, in the latent space. This highlights the link between the gene latent space and the cancer
context that we made a part of our framework. Furthermore, it underlines the relevance of our embeddings for the identification
of putative cancer-related genes, discussed in the following section.
Finally, as pathways and complexes are embedded in the same latent space, we investigate their positioning with respect
to genes. In particular, we evaluate if a gene is embedded closer to its associated higher-order entities, i.e. pathways and
complexes, than to those to which it has not been associated yet. To this end, we compute the cosine distances in the latent space
between a gene and its associated pathways and complexes, termed “intra–pathway” and “intra-complex” distances, as well as
the distances between the gene and all non-associated pathways and complexes, termed “exo–pathway” and “exo-complex”
distances. We observe that genes are embedded closer, on average, to their associated higher-order entities than they are to those
that they are not associated to (see Figure 2.d.), with average distance below 0.5 between a gene and associated entities and
above 0.9 between a gene and non-associated entities. These results are significant according to a Mann–Whitney U statistical
test (p-value ∼ 0 in both cases) and underline the relevance of the joint embedding of genes with related higher-order molecular
structures in the same latent space. This also suggests that our framework could be used for identifying new genes that are
involved in, or interact with pathways and protein complexes, which we leave for future work.
Predicting cancer type associations
To extract new knowledge for each cancer type, we use our context-aware embeddings to suggest cancer–drug and cancer–gene
associations. In particular, we train classifiers to predict known associations based on our entities’ embeddings and use
the trained classifiers to predict new associations (see Methods). We first normalise all embeddings to have a unit norm.
The normalisation step is crucial for the transfer of a classifier between types of entities that we discuss in the following
section. Then, for each cancer–drug pair (or cancer–gene pair), we define the pair’s representation by the concatenation of
the embeddings of its components, i.e. the concatenation of the cancer’s embedding vector with the drug’s embedding vector
defines the feature vector of the pair. Finally, we use boosted decision trees as simple classifiers that take as input a pair’s
representation and output the association’s scores of its component (see Figure 1.c.). We choose boosted decision trees due to
their simplicity and high performances in a number of competitions22.
In the first validation step, we systematically evaluate the performance of our approach with a 10-fold cross-validation
using both the Area Under the Receiver Operating Curve (AUROC) and the Area Under the Precision recall Curve (AUPRC)
and compare our results to state-of-the-art predictive methods. In the second step, we investigate the top 10 drugs and genes
associated to cancer types by our methodology. Each pair is scored based on the average of the standardised scores given by 10
classifiers trained for the cross-validation (see Methods for details). In this step, we only consider drugs and genes that were
thus far not associated to any cancer type in the ground-truth data (introduced in each subsection) to avoid trivial cases of
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Figure 3. Performances of our cancer–drug association predictor (left column) and cancer–gene associations predictor (right
column). The bar charts give the performances of our classifiers measured with 10-fold cross-validation in terms of Area Under
the Receiver Operating Characteristic (AUROC) and Area Under the Precision Recall Curve (AUPRC). The tables give the top
ten associations between cancers and drugs (panel b.) and genes (panel d.) that are not associated with any cancers in our data.
Drugs or genes highlighted in bold font have been associated to cancer. The support column in the bottom right table indicates
which database lists a link between the gene and cancer.
information transfer from one cancer to another, which typically happens when one drug, or one gene is associated to a majority
of cancers. We perform a manual literature curation to validate the top results.
Our model predicts relevant treatment
To predict cancer–drug associations, we train classifiers to identify known associations that we collect from DrugCentral23
(last updated October 2018). We define our positive set with DrugCentral treatment options and consider all non-reported
associations for our negative set. Our classifier takes as input the concatenation of the normalised embeddings of a drug
and a cancer type and outputs their association score. We compare our results to four baseline methods: Non-negative
Matrix Factorization Reconstruction (NMFR), Measure-based Bi-directional Random Walks (MBiRW)24, Drug Repositioning
Recommendation System (DRRS)25, and Bounded Nuclear Norm Regularization (BNNR)26 (see Methods for implementation
details).
We observe that our approach significantly outperforms the competing methods (see Figure 3.a.). BNNR achieves slightly
better AUROC scores (∼ 0.99 compared to our ∼ 0.97), but it scores significantly lower than our framework in terms of
AUPRC (∼ 0.25 compared to our ∼ 0.5). These results show the relevance of our method when compared to the state-of-the-art
drug re-purposing approaches. We analyse further the results of our approach through literature curation for the top-scoring
drugs that are not associated with any cancer types in DrugCentral.
Among the top 10 drugs that are the most associated to cancer types by our classifiers (see Figure 3.b.), a majority is
recorded in DrugBank as investigational, or approved for the treatment of some cancers. The approved predicted drugs either
are not present in DrugCentral, as their approval postdates the DrugCentral release, or target a cancer type not considered in this
study. We discuss below supporting information for our top 3 predicted drugs. We provide validations of all of our predictions
in the Supplement.
DB05916 (CT-011) targets gene PDCD1, which has immunomodulating and antitumor activities. CT-011 is currently being
investigated for the treatment of tumours and unspecified cancers27. DB14707 (Cemiplimab) is an FDA approved drug for the
treatment of advanced cutaneous squamous cell carcinoma27. Our classifier suggests that it could be used to treat lung cancer
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and notably lung squamous cell carcinoma (LUSC). DB05101 (Matuzumab) is an investigational drug that targets EGFR gene,
which is often associated with cancers, including lung cancers28.
The manual literature curation highlights that our predicted drugs are often investigated, or approved for the treatment of
forms of cancer and that their targets, or mechanisms of actions, can be linked to the specific cancer types we predict. Overall,
the analysis strongly supports our methodology.
Our framework identifies genes relevant to cancer types
Based on known cancer genes from IntOGen29, we train classifiers to identify associations between genes and cancer types.
Our positive set is constituted of cancer–driver associations. All non-reported associations are considered as part of our
negative set. As above, our classifier takes as input the concatenation of the normalised embeddings of a gene and a cancer
type and outputs their association score. We compare the performance of our method with the following state-of-the-art
methods: Non-negative Matrix Factorisation Reconstruction (NMFR), Network Based Integration (NBI)30, LOTUS31, and
Subdyquency32. The methods were developed to predict cancer-related genes in slightly different contexts and are adapted to
our problem here (see Methods for details).
We observe that our approach outperforms the competing methods (see Figure 3.c.) in terms of AUROC, which is over 0.9
for our method compared to below 0.8 for the other approaches, and in terms of AUPRC which are around 0.4 for our approach
compared to below 0.25 for the other methods. We further look at the top 10 genes that are identified by our method (see Figure
3.d.). We use the Cancer Gene Census (CGS)33 and Candidate Cancer Gene Database (CCGD)34 to find known associations, as
well as literature curation (both databases were accessed in August 2019).
We observe that our top 10 scoring genes are listed in either the Candidate Cancer Gene Database (CCGD), or the Cancer
Gene Census (CGC) as linked to at least one form of cancer. Furthermore, the pairs MDM2–LIHC, HERC1–COAD, HERC1–
READ, SMC3–LAML, NCOA3–BRCA, and CHD6–BRCA are associated in CCGD. Additionally, KAT2B (PCAF) activity
has been linked to cancers, and in particular, to breast cancers, in the literature35–37. MDM2 has also been associated with
breast cancer38. SP1 expression has been linked to breast cancer in multiple prior studies39–41. For each of these three genes,
we stratify our BRCA cohort into two groups: patients having higher than average expression of the gene and patients having
lower than average expression of the gene. We compute a logrank statistical test (with 0.05 cut-off) and observe that for each of
the three genes, the patient groups have significantly different survival rates with p-values 0.002 for KAT2B, 0.026 for MDM2,
and 0.039 for SP1 (see Supplementary Figure 2.a-c. for Kaplan-Meir plots). For each of the three genes, higher expressions are
associated with lower survival rates. We provide validations for the remaining predictions in the Supplement.
The literature curation highlights that each gene identified through our approach is relevant to the associated cancer type,
with support through existing research and databases, as well as statistical evidence for a connection between gene expression
level and patient prognosis. Thus, this supports our methodology.
Re-purposing classifiers
Links between types of entities are not always known or available (e.g., associations between cancer type and protein complexes
or associations between patients and drugs), which prevents us from using the same methodology to derive new knowledge.
However, our framework allows for extrapolating those links from known associations between other types of entities. Our
approach relies on the previously observed fact that, by design, some entities are embedded in the same latent spaces (e.g.,
genes, pathways, and complexes or cancer types and diseases). We have further shown in the first section, that the relative
location in the latent space of related entities was biologically consistent, i.e. related entities are closer to each other than
non-related entities. Based on these observations, we postulate that a classifier trained from the embeddings of a given
type of entities can be re-purposed to predict from the embeddings of another type of entities. For instance, classifiers that
learnt to associate genes to cancer types can be used to predict which biological pathways or protein complexes could be
associated with which cancer types. This could effectively provide mechanistic insights into the inner workings of cancers
by identifying affected higher-order cellular structures and functions. Furthermore, by pushing this logic further, one can
derive patient-specific predictions, particularly patient-specific drugs. This is, however, difficult to validate due to the lack of
patient treatment information in ICGC database. Thus, we focus below on the analysis of top associations between higher-order
cellular structures and cancer types.
Our re-purposed classifiers identify cancer-related protein complexes
To obtain the association score between a cancer type and a protein complex, we simply feed the concatenation of the normalised
embeddings of both entities to the 10 classifiers trained to predict cancer–gene associations. The average of the standardised
scores across all classifiers gives the final association score.
To the best of our knowledge, there are no comprehensive database reporting associations between cancers and protein
complexes. Thus, we are unable to provide global validation scores for our predictions. We proceed by validating the top 3
scoring protein complexes manually (see Table 1) below. We provide validations of all of our predictions in the Supplement.
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Protein Complex Predicted for
IL6:sIL6R:IL6RB:JAKs all cancers
p-7Y-RUNX1:PTPN11 BRCA;BLCA;PAAD;LUSC;GBM
R-HSA-1112759 BRCA;LAML;BLCA
Integrin alpha2bbeta3:SRC BRCA;BLCA
R-HSA-1112753 BRCA;LAML;BLCA;LGG;GBM
R-HSA-1112563 BRCA
SAM68:p120GAP BRCA
JAKs:OSMR BRCA
IL6ST:JAKs BRCA
R-HSA-9632399 BRCA
Table 1. Top 10 protein complexes associated to cancer types.
IL6:sIL6R:IL6RB:JAKs complex plays a role in interleukin 6 signalling, which is linked to cancer42. The complex
is associated with JAK family of kinases, themselves tied to cancer43. p-7Y-RUNX1:PTPN11 complex is involved in the
regulation of RUNX1 expression and activity. RUNX1 has been linked to various cancer, sometimes with opposite effects34.
However, regardless of its precise role in a given cancer, the regulation of RUNX1 appear to be of critical importance as over-
or under-expression can have an important impact on the development of cancer44. Tyrosine phosphorylated IL6 receptor
hexamer:Activated JAKs:Tyrosine/serine phosphorylated STAT1/3 complex (R-HSA-1112759) is involved with interleukin 6
signalling and more specifically serine phosphorylation of STAT family of transcription factors. We have seen previously that
interleukin 6 signalling has been linked to cancer. Furthermore, STAT has been linked to various cancers, including breast
cancer (BRCA) that our results associate to the protein complex45.
The literature curation highlights that our predicted associations between protein complexes and cancer types are supported
by the existing literature. Thus, the analysis demonstrates the validity of our classifier re-purposing approach, as well as the
ability of our framework to extract cancer mechanisms at the level of protein complexes.
Our re-purposed classifiers identify cancer-related biological pathways
Similarly, we can predict associations between cancer types and biological pathways. The association score between a cancer
type and a biological pathway is obtained by simply feeding the concatenation of the normalised embeddings of both entities to
the 10 classifiers trained to predict cancer–gene associations. The average of the standardised scores across all classifiers gives
the final association score.
CTD database46 gives associations between diseases and pathways based on shared associated genes and can be used
for global validation. We achieve an AUROC score of 0.65± 0.01 and an AUPRC score of 0.66± 0.01, which indicates
predictions significantly better than random (p-value∼ 0) for our re-purposed classifiers. However, note that 52% of all possible
associations between our set of cancer types and our set of pathways are reported in the database. This indicates that the
condition for association used by CTD might not be sufficiently stringent. This motivates the following manual literature
curation to validate our top 10 scoring biological pathways. We discuss the first 3 predicted pathways below and provide
validations of all remaining predictions in the Supplement.
Pathway Predicted for
R-HSA-112411 all cancers
R-HSA-2262752 BRCA
R-HSA-5654688 BRCA;GBM;BLCA;LGG;PAAD;LAML;
LUSC;STAD;SKCM;LUAD;UCEC
R-HSA-5654699 BRCA
R-HSA-8953897 BRCA
R-HSA-110056 BRCA
R-HSA-389357 BRCA
R-HSA-5654719 BRCA
R-HSA-9603381 BRCA
R-HSA-8866910 BRCA
Table 2. Top 10 biological pathways associated to cancer types.
MAPK1 (ERK2) activation pathway (R-HSA-112411) and MAPK3 (ERK1) activation pathway (R-HSA-110056) have
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been linked to numerous cancers, such as breast cancer, as discussed in the previous section, and colorectal cancer47. The
ERK MAPK pathway is critical for cell proliferation and thus is naturally often connected to cancers. Cellular responses to
stress pathway (R-HSA-2262752) is a subpathway of the cellular responses to external stimuli pathway (R-HSA-8953897)48.
Anticancer treatments are often successful when able to induce apoptosis through external stimuli that induce cellular stress49.
For instance, tumour suppressor gene P53 can be stimulated via cellular stress50. Thus, perturbation to those pathways might
lead to cancer onset and resilience to treatment.
The literature review highlights the ability of our classifier re-purposing approach to identify associations between biological
pathways and cancer types that are supported by the existing literature. Thus, this analysis underlines the ability of our
framework to extract cancer mechanisms at the level of biological pathways.
Discussion
We introduce a two-step framework to perform data integration, feature reduction, and classification to uncover cancer-related
knowledge. First, we develop an integrative non-negative matrix factorisation model to jointly embed entities in multiple
connected latent spaces based on relational data between those entities. We show that relative positions of entities in our latent
spaces are consistent with what we know about them. For instance, we show that genes group in functional domains and are
close to associated higher-order molecular structures (pathways and complexes) embedded in the same latent space. Patients
tend to be closer to other patients having the same diagnosis and to the diagnosis itself. By taking a pan-cancer approach, we
are able to identify groups of patients with similar molecular manifestations spanning various cancers, confirming that cancer
classification may need to be rethought on a global scale and the need for initiatives such as PCAWG7. Based on known drug
indications for the treatment of each cancer type and known cancer type driver genes, we train classifiers through which we
can predict relevant new associations for each cancer type. Due to the joint embedding of different entities in the same latent
space, we hypothesised that classifiers trained to identify associations with one type of entities could be re-purposed to derive
associations with other, less-studied, entities. In this way, we can uncover biological mechanisms affected by each cancer type.
Interestingly, our work opens the door for actionable precision medicine. Through the joint embedding of cancers and
patients, classifiers trained on high-level knowledge about cancer types can be re-purposed to help identify patient-specific
information, such as potential drug treatment. However, as the biological validation of such predictions is difficult, requiring
cell-line experiments or clinical trials, we leave it for future work.
Our framework is general and flexible and can accommodate additional and different data. While we focus on cancer here,
our work paves the way for general cross-diseases analysis that could be useful to identify treatment re-purposing based on
molecular similarities among medical conditions.
Methods
Data source and processing
We downloaded protein-protein interactions (PPI) data from Biogrid (version 3.5.176). We only keep interactions that have
been validated experimentally using yeast-to-hybrid or affinity capture techniques. We obtained protein complexes data from
CORUM and Reactome databases (both accessed in April 2019). Reactome is also used to collect all existing pathways of
which we only keep pathways that have a traceable author statement (TAS). We further remove disease pathways which are
only relevant in the associated disease context.
Patients data are obtained from the DCC Data release of the International Cancer Genome Consortium. We collected
patients from 21 cancer cohorts from TCGA studies (see Table 3) and kept patients that have RNA-sequencing data, which
adds up to 7,998 patients. We consider all Single Nucleotide Variations (SNV) reported in the data releases.
We consider the set of 15,224 genes whose transcripts are measured for by the RNA-sequencing technology across all
datasets and that have at least one PPI with another selected gene according to BioGrid data. We derive a gene expression
vector from RNA-seq measurement for each patient that is normalised to Transcripts Per Million (TPM) and rescaled using
logarithm in base 2, i.e. the expression score of a gene is given by log2(TPM+1). Note that 559 patients have do not have any
mutation on any of the 15,224 genes considered.
Drug–target and chemical data is obtained from DrugBank (version 5.1.3)27. We consider all drugs that are approved,
experimental, or investigational. Drugs chemical similarity is computed using the Tanimoto similarity51 between drugs smile
representations. The details of the data used can be found in Table 4.
Genes’ annotations used for the enrichment analysis are obtained from Gene Ontology (GO)52 (release 10/06/2019). We
keep annotations that have an experimental evidence code (one of EXP, IDA, IPI, IMP, IGI, and IEP). We consider all three
GO annotation subtypes separately: Biological Processes (GO–BP), Molecular Function (GO–MF) and Cellular Component
(GO–CC). For each, we build a directed acyclic graph (DAG) that connects annotations based on “is a” relationships (we use
the go-basic.obo file giving annotations relationships available on GO’s website). Then, we propagate the annotations for each
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Cancer Cohort size Abbreviation Cancer Cohort Size Abbreviation
Acute Myeloid Leukemia 173 LAML Bladder Urothelial Carci-
noma
295 BLCA
Brain Lower Grade Glioma 439 LGG Breast invasive carcinoma 1,041 BRCA
Cervical squamous cell carci-
noma and endocervical ade-
nocarcinoma
259 CESC Colon adenocarcinoma 428 COAD
Glioblastoma multiforme 159 GBM Head and Neck squamous
cell carcinoma
480 HNSC
Kidney renal clear cell carci-
noma
518 KIRC Kidney renal papillary cell
carcinoma
222 KIRP
Liver hepatocellular carci-
noma
173 LIHC Lung adenocarcinoma 477 LUAD
Lung squamous cell carci-
noma
428 LUSC Ovarian serous cystadenocar-
cinoma
262 OV
Pancreatic adenocarcinoma 142 PAAD Prostate adenocarcinoma 375 PRAD
Rectum adenocarcinoma 153 READ Skin Cutaneous Melanoma 430 SKCM
Stomach adenocarcinoma 415 STAD Thyroid carcinoma 500 THCA
Uterine Corpus Endometrial
Carcinoma
508 UCEC
Table 3. List of cancer types considered in this study with associated abbreviations from TCGA.
Data Size Density Symbol
Gene expression 7,998×15,224 n.a Xexp
Gene SNV 7,998×15,224 1.7% Xsnv
Patient cancer type 21×7,998 n.a. Xpct
PPI 15,224×15,224 0.21% Xppi
Protein complexes 7,022×15,224 0.05% Xpc
Biological pathways 1,650×15,224 0.32% Xbp
Drug–target 7,333×15,224 0.013% Xdt
Drug tanimoto similarity 7,333×7,333 n.a. Xts
Table 4. Details of the data used. The columns correspond to: 1) the type of data, 2) the size of the matrix representing the
data, 3) the density, where applicable, indicates the percentage of the existing links between the entities out of all possible links,
and 4) the symbol used in the document to refer to the matrix containing the corresponding data.
gene up the corresponding DAG, which means that we add to the set of annotations of a gene the union of ancestors of the
annotations. We remove annotations that annotate less than 0.1%, or more than 10% of the 15,224 genes considered, i.e. we
prune annotations that are either too rare, or too common. We give the statistics of annotations in Table 5
GO subtype GO–BP GO–MF GO–CC
Number of annotations 2,322 538 366
Percentage of genes annotated 50% 43% 45%
Table 5. GO annotations statistics for all GO subtypes.
Non-negative Matrix Factorizations
Matrix factorizations approaches aim to approximate a matrix X by the product of n smaller matrices Fi, i ∈ {1..n}, called
factors, i.e. X ≈∏i Fi. Mathematically, this amounts to finding factors Fi, under user defined dimensional contraints, that
minimize the equation ‖X−∏i Fi‖2F , where ‖·‖F represents the Frobenius norm of a matrix. Non-negative matrix factorizations
techniques add a positivity contraint on the factors, i.e. ∀i,Fi ≥ 0.
The objective is to obtain lower dimensional representation that captures the essence of the data and can be used to identify
missing entries through the matrix completion property. In this work, we use three variants of non-negative matrix factorisations
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approaches.
NMF decomposes a rectangular matrix X ∈ Rm×n in the product of two positive factors F ∈ Rm×k+ and G ∈ Rn×k+ , with
k ≤ min(m,n), such that ‖X −FGT‖2F is minimized. With NMF, the embeddings, given by F and G, of the two groups of
entities whose relational data is given by X , are in the same latent space.
NMTF decomposes a rectangular matrix X ∈ Rm×n in the product of three positive factors F ∈ Rm×k1+ , S ∈ Rk1×k2+ and
G ∈ Rn×k2+ , with k1,k2 ≤min(m,n), such that ‖X−FSGT‖2F is minimized.
SNMTF decomposes a symmetric matrix X ∈ Rn×n in the product of two positive factors G ∈ Rn×k+ and S ∈ Rk×k+ , with k ≤ n,
such that ‖X−GSGT‖2F is minimized.
Our Integrative Framework
We propose a framework that jointly integrates all data sources together by using a mixture of non-negative matrix factorisations
to obtain for each entity an embedding that takes into account the full context of our task. We minimize the following general
objective functionL over all G· and S· factors:
L = min
G·,S·
∑
x∈{exp,snv}
‖Xx−GpSxGTg ‖2F + ∑
x∈{pc,bp}
‖Xx−GxGTg ‖2F (1)
+‖Xppi−GgSppiGTg ‖2F +‖Xpct −GctGTp‖2F
+‖Xts−GdStsGTd ‖2F +‖Xdt −GdGTg ‖2F ,
where, henceforth, each XD represents the matrix associated to data type D, see nomenclature in Table 4, each GE factor gives
the embeddings of the entities of type E, with subscripts g, p, ct, d, bp, and pc corresponding, respectively, to genes, patients,
cancer types, drugs, pathways, and complexes. S· factors are optimized over, but not used for the analysis.
The integration of the various data sources is achieved by sharing factors across the NMF sub-objectives that constitute
our global objective function L . For instance, the factor Gg, corresponding to the genes embeddings, is shared by all
decompositions that involve genes which corresponds to the factorisation of PPI data (Xppi), the factorisations of patients
molecular data (Xexp and Xsnv), the factorisation of drug–target data (Xdt), and the factorisations of higher-order biological
entities (Xpc and Xbp). Through this factor sharing and joint optimisation, the framework is able to harness the relevant
information contained across the data sources to derive meaningful embeddings.
Optimization
The minimisation of the objective function given in Equation 1 is achieved through an iterative optimisation process. We use in
our framework multiplicative update rules53 designed to maintain non-negativity of all the factors in the decomposition.
We use an initialization strategy based on the truncated singular value decomposition (SVD) for all factors that has shown
better performances than random initialization13, 54 and has the advantage of giving deterministic solutions. Specifically,
consider a factor G ∈ Rn×k involved in the decomposition of l data matrices Xi, i ∈ {1..l}. Without loss of generality, we
assume that G is the right hand side factor in the decompositions, i.e. ∀i,Xi ≈ GFi. We denote by Ui the right hand side term
in the SVD decomposition of Xi ( Xi =UiSiV Ti ). We introduce U
+
i = max(Ui,0) and U
−
i = max(−Ui,0). We then denote by
U˜i ∈ Rn×k the matrix where each column is defined by
U˜i( j) =
{√
si( j)U+i ( j), if ‖U+i ( j)‖ ≥ ‖U−i ( j)‖√
si( j)U−i ( j), otherwise
,
where M( j) denotes the jth column of the matrix M and si( j) is the jth largest singular value of Xi. Factor G is then initalized
as 1l ∑
l
i=1 U˜i+ ε . We initialize the central matrix in NMTF decompositions to I+ ε , where I denotes the identity matrix. Under
the multiplicative update rules, any entries initialized to zero would stay null. Hence, we add a small ε everywhere to allow all
entries to vary.
The iterative optimisation is ran either for 200 epochs or until the relative variation of the objective function between two
consecutive epochs is lower than 10−4, i.e. when |Lt+1−Lt |Lt ≤ 10−4 whereLt corresponds to the value of the objective function
at iteration t.
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Boosted decision tree
In the main document, we used boosted decision trees to predict cancer type associations with entities that are part of our
framework based on the embeddings derived from the Joint NMF optimisation step. A decision tree classifier partitions the
input data iteratively based on features. Boosting signifies deriving a strong classifier from the serial associations of weak
classifiers. In our case, the base classifiers are decision trees. The boosted algorithm iteratively adds decision trees to the
classifier with the aim of reducing the error of the previous classifier55.
We discuss here the implementation details that we used. First, we use boosted decision trees from the xgboost package22.
Boosted decision trees have different hyperparameters that control various aspect of the algorithm: η controls the learning
rate, γ corresponds to a threshold under which a leaf node of the decision tree is not split anymore, the maximal depth of a
decision tree, and λ controls the L2-regularization (for more details see22). We perform a 10-fold cross-validation to fix those
hyperparameters with η ∈ {0.25,0.5,0.75}, γ ∈ {0,10}, max depth∈ {6,12}, and λ ∈ {1,10,100}. The best set of parameters
is chosen as the one that leads to the classifier with the highest AUROC score in the associated task. Note that we also use
early-stopping during training with an 80%/10%/10% train/validation/test split of our data. We use all 10 classifiers trained
during the cross-validation process to derive an association score for each possible pair. To ensure that the scoring of the 10
classifiers is comparable, we rescale the output scores to have 0 mean and unit variance. The average of all classifier scores
then gives the final association score of an entity pair.
Baselines
We contrast the performances of our trained boosted decision tree with those of the state-of-the-art methods for the prediction
of cancer type associations with genes and drugs. We chose baselines based on the availability of source code (or detailed
implementation description), the quality of reported performances, and the concordance of input data with ours. Our implemen-
tation of each method is available in the Supplementary Files. When a method requires hyperparameters tuning, the criterion
used to identify the best set of hyperparameters is always the AUROC score of the classifier in the associated task.
Non-negative Matrix Factorization Reconstruction (NMFR) is based on the reconstruction of the data after factorizations
and is the simplest approach based on our framework. The idea is based on the matrix completion property observed in matrix
factorizations methods18. Here, we propose a simple method that makes use of the link between factors to extract entities’
association scores. For instance, cancer–gene association scores, CG, are given by
CG = GctGTp Gp
(Sexp+Ssnv)
2
GTg ,
where entry (i, j) of matrix CG gives the association score between cancer type i and gene j. Cancer–drug association scores,
CD, are given by
CD = GctGTp Gp
(Sexp+Ssnv)
2
GTg GgSdtG
T
d ,
where entry (i, j) of matrix CD gives the association score between cancer type i and drug j.
Performances are measured by how well those association scores correlate to IntOGen cancer–driver data and DrugCentral
cancer–drug data using AUROC and AUPRC.
MBiRW24 was proposed to identify potential new indications for the existing drugs. The method is based on a bi-directional
random walk using a drug similarity network, a disease similarity network, and a bipartite network connecting diseases to drugs.
The authors report good performances against known ground-truth relative to the competing methods and manually validate de
novo predictions.
Here, the drug similarity network adjacency matrix is given by the drug Tanimoto similarities matrix Xts. We define the
cancer similarity network Xcc based on a molecular similarity between cancers. We first associate to each cancer two molecular
signatures given by the average of patients gene expression data and SNV data. From each type of data, we define a cancer
similarity network that corresponds to the cosine similarity of their molecular signatures. We denote by Xcc the final cancer
similarity network corresponding to the average of those two similarity networks. Note that the authors use a different disease
similarity matrix, the source of which is currently offline. Finally, we use cancer–drug data from DrugCentral to define a
bipartite network in which an entry is set to 1 to indicate an association between the corresponding drug and cancer, and 0
otherwise.
The authors propose an iterative method that follows the step given in Algorithm 1.
We perform a 10-fold cross-validation to select hyperparameters α ∈ {0.1,0.3,0.5,0.7,0.9} and M ∈ {2,5,10,20} (note
that the authors set M = 2, and search for α). In each run, 10% of known cancer–drug associations are masked in the input to
the algorithm and we evaluate how well MBiRW is able to retrieve those.
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Data: cancer–cancer network Xcc, drug–drug network Xts, cancer–drug network CD, parameter α , maximum number of
iterations M
Result: cancer–drug associations scores O
DD = D
− 12
ts XtsD
− 12
ts ;where Dts is a diagonal matrix where entry Dts(i, i) = ∑ j Xts(i, j)
CC = D
− 12
cc XccD
− 12
cc ;where Dcc is a diagonal matrix where entry Dcc(i, i) = ∑ j Xcc(i, j)
R0 = CD∑CD ; where ∑CD gives the number of non-zero entries in CD
O = R0; niter = 0;
while niter ≤M do
L = α ·O ·DD+(1−α) ·R0;
R = α ·CC ·O+(1−α) ·R0;
O = L+R2 ;
niter = niter +1;
end
Algorithm 1: MBiRW algorithm.
DRRS25 was proposed to identify potential new indications for the existing drugs as well. The method is based on the matrix
completion property of Singular Value Thresholding Algorithm (SVT) using a drug similarity matrix, a disease similarity
matrix, and a disease–drug indication matrix. The authors report good performances against known ground-truth relative to the
competing methods and further use their methods to predict indications for new drugs, validating novel associations.
For our purposes, we use the Tanimoto drug similarity matrix Xts, the cancer–cancer similarity matrix derived from ICGC
molecular data Xcc, and cancer–drug associations from DrugCentral Xcd . The authors define the block matrix A
A =
(
Xts XTcd
Xcd Xcc
)
,
and feed it to the SVT algorithm. The maximum number of epochs is set to the minimum between the number of cancers and
the number of drugs. The iteration with the highest AUROC gives the final predictions. We perform a 10-fold cross-validation
to evaluate the performance of the algorithm. In each iteration, we mask 10% of known cancer–drug associations and evaluate
how well the algorithm retrieves them.
BNNR26 was developed for re-purposing of drugs. The method is also based on the completion property of SVT. The
algorithm follows the steps given in Algorithm 2. Compared to DRRS, BNNR incorporates a regularisation term to balance
the approximation error and the rank properties and thus can handle the noisy drug–drug and disease–disease similarities. It
also adds a constraint that clips the association scores to the interval [0,1]. The authors found that those additions benefited
performances compared to DRRS for retrieval of known associations. They further manually validated the top-scoring
associations through literature curation.
We perform a 10-fold cross-validation to evaluate the performance of the algorithm and fix the hyperparameters α ∈
{0.1,1,10,100} and β ∈ {0.1,1,10,100}.
Network Based Integration (NBI)30 was developed to identify cancer-related genes that are not necessarily mutated or
differentially expressed. The method is based on network heat diffusion process over a molecular network. The original
paper focuses on a specific cancer for which they collect differential gene expression data and SNV data. The authors assess
performances by first measuring how accurately their method retrieves known cancer driver genes and then validate novel
cancer–gene associations.
Network heat diffusion is defined by the iterative update of scores X0 associated to the network’s nodes following the
equation
Xn+1 = αWXn+(1−α)X0,
where W denote the network data and Xn corresponds to the updated scores after n iterations. The iterative process terminates
when ‖Xn+1−Xn‖2 < 10−6.
The authors set W to the PPI normalized adjacency W = ∆−
1
2 Xppi∆−
1
2 , where ∆−
1
2 is a diagonal matrix where entry i
corresponds to the degree of gene i in the PPI network. The authors use the diffusion process both on patients differential gene
expression and SNVs, obtaining two diffused vector scores per patient. They then handcraft 13 cancer-specific features for
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Data: block matrix A, hyperparameters α and β
Result: cancer–drug associations scores W
tol1 = 2 ·1e−3; tol2 = 1e−5;
M = 300; niter = 0;
s1 = 1; s2 = 1;
X = A; Y = X ; W = X ;
mask = T > 0;
while niter ≤M or tol1 < s1 or tol2 < s2 do
F = 1b (Y +αT )+X ;
W = F− αα+β Fmask;
W [W < 0] = 0; W [W > 1] = 1;
Xt = svt(W − 1β Y, 1β );
Y = Y +β (Xt −W );
st = s1; s1 =
‖Xt−X‖F
‖X‖F ;
s2 =
|s1−st |
max(1,|st |) ;
X = Xt ; niter = niter +1;
end
Algorithm 2: BNNR algorithm.
each gene based on the results. Those features are then used as input to a logistic regression classifier trained to predict known
cancer drivers.
As differential gene expression is not available to us, we use the same gene expression values that are input to our framework.
Since our analysis is across cancers, we compute gene features for each cancer types, i.e. each cancer–gene pair is associated
with a 13-dimensional feature vector. The method has two hyperparameters: α for the heat diffusion process, and C that controls
regularisation of the logistic classifier. We perform a 10-fold cross-validation procedure to pick the best pair of hyperparameters,
with α ∈ {0.25,0.5,0.75} and C ∈ {0.01,1,100}, and to evaluate the performance of a logistic regression classifier trained on
those features to predict cancer-specific driver genes.
LOTUS31 is a method that achieved the state-of-the-art results for the more specific tasks of identifying oncogenes and tumour-
suppressing genes. Each task is tackled separately, and each with 3 different gene features that are not available to us. However,
the method can be adapted to the simpler task of retrieving cancer driver genes. To this end, we use gene expression data, SNVs,
and gene methylation data, that are available in ICGC, as gene features. A patient’s gene methylation is defined as the average
beta value of all associated CpG islands.
The authors of LOTUS propose both a cancer-specific framework and a pan-cancer framework; we use the latter here. The
method revolves around the Support Vector Machine (SVM) algorithm. The authors first define for each sample–gene pair 3
features that are then averaged across all samples to give the final gene features. In their work, the final features correspond to
the number of damaging missense mutations, the total number of missense mutations, and the entropy of the spatial distribution
of the missense mutations on each gene, for the prediction of oncogenes. For the prediction of tumour-suppressing genes,
the features are the number of frameshift mutations, the number of loss-of-function mutations, and the number of splice site
mutations. Note that when defining those features, the authors do not differentiate across cancer types. In our case, the features
correspond to the mutation frequency, the average gene expression, and the average gene methylation across all samples. To
ensure that those features are comparable, we normalise the distributions to have 0 mean and unit variance.
The authors then define both a gene kernel Kg and a cancer kernel Kc. The gene kernel is defined as the average of a kernel
corresponding to a gene similarity matrix derived from 3-dimensional features defined above and a kernel derived from the PPI
network. We have
Kg =
1
2
(
ΦΦT + e−L
)
,
where Φ ∈ R15,224×3 represents the gene features and L is the normalized Laplacian of the PPI network, L = I−D− 12 XppiD− 12 ,
I represents the identity matrix and D the diagonal matrix with entries corresponding to the degree of each node in the PPI
network. The cancer kernel is defined as the sum of three kernels
Kc =
1
3
(I+ J+Xcc) ,
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where I represents the identity matrix, J corresponds to the matrix filled with ones, and Xcc is a cancer similarity matrix. As
above, we use the cancer similarity matrix defined based on cancers molecular similarities.
The final kernel K for (cancer,gene) pairs used for pan-cancer analysis is defined by
K
(
(c,g),(c′,g′)
)
= Kc(c,c′)×Kg(g,g′),
where c and c′ represent cancers and g and g′ represent genes. The hyperparameter of the model corresponds to the regularisation
coefficient C of the SVM algorithm. Due to the large size of the full kernel K, we use the same strategy as the authors of
LOTUS and randomly sample negative (cancer,gene) pairs from all (cancer,gene) pairs that are not reported in IntOGen. This
effectively boils down to using a submatrix of kernel K as input that contains as many positive (cancer–driver associations)
and negative pairs. As before, we perform cross-validation to pick C ∈ {1,10,100,1000} and evaluate the performance of the
method on our task.
Subdyquency32 is a method based on random walks on a network to identify cancer drivers. It achieves the state-of-the-art
results for the retrieval of known cancer drivers. The framework is defined for specific cancers and we extend it to pan-cancer.
In their framework, the authors build a network between “outlier” and mutated genes. The outlier genes are genes whose
expression is significantly different with respect to the cohort. They correspond to genes with absolute z-score strictly greater
than 2. The set of outlier (mutated) genes is defined as all genes being at least outlier (mutated) for one patient. Here, we
consider all cancers together to define those sets. Directed interactions between genes are obtained from the Functional
Interactions (FI) network56 derived from Reactome48. We downloaded the 2019 version of the FI network. The authors define a
bipartite graph between the two sets of genes whose edges correspond to directed links in the FI network. The edge weights are
defined based on the localisation of proteins in a cell as given by the COMPARTMENT database57 (see the original paper for
details). As done by the authors, we downloaded all data relating to human regardless of evidence type (obtained in April 2020).
We denote the adjacency matrix of this bipartite graph with W ∈ Rnm×no , where nm and no represent the number of mutated and
outlier genes, respectively. Then, for each patient p, the authors define a feature vector for the outlier gene set, denoted by Op,
and another one for the mutated gene set, denoted by Mp. Specifically, consider gene i in the mutated set. If gene i is mutated
for patient p, then Mp(i) is set to the mutation frequency of gene i in the cohort of patients having the same cancer as p, and 0
otherwise. For gene j in the outlier set, if j is not an outlier for patient p, then Op( j) is set to 0, if j is an outlier and is also in
the mutated set, then Op( j) is set to Mp( j), else it is set to the outlier frequency of j across the set of patients having the same
cancer as patient p. The authors then propose the three steps procedure simulating a random walk on the bipartite graph using
both feature vectors
Rmp = αMp+(1−α)WOp,
Rop = αOp+(1−α)W T Rmp ,
Rmp = αMp+(1−α)WRop,
where α ∈ [0,1] is the sole hyperparameter of the model. The final cancer–gene scores are derived by summing the Rmp vectors
across patients. Higher scores indicate a stronger associations between a cancer and a gene. We perform a cross-validation to
pick α ∈ [0,1] and evaluate the performance of the method on our task.
Data Availability
The data is available at https://life.bsc.es/iconbi/context_aware_embeddings/index.html.
Code Availability
The c++ library for the joint factorisation is available at github.com/tgaudele/nmfif.
The analysis code, including baselines methods, is available at https://life.bsc.es/iconbi/context_aware_
embeddings/index.html.
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